Pyxis Oncology (PYXS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PYXS Pyxis Oncology

Watchlist

1.220
-0.060-4.69%

Close Feb 24 16:00 ET

72.55MMarket Cap-1.15P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
Yahoo FinanceFeb 23 07:53 ET
Pyxis Oncology Initiates New PYX-201 Trial, Initiates Cohort Expansions
TipRanksFeb 4 07:37 ET
Express News | Pyxis Oncology Initiates New Pyx-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
ReutersFeb 4 07:30 ET
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $8
Moomoo NewsDec 20, 2024 13:31 ET · Ratings
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $5
Moomoo NewsDec 20, 2024 13:31 ET · Ratings
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Moomoo NewsDec 20, 2024 13:31 ET · Ratings

Comments

Teddy123

Feb 4 06:33

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

$Pyxis Oncology (PYXS.US)$
Major Clinical Advance: Pyxis Teams with Merck for Groundbreaking Cancer Therapy Trial

103365182

Dec 23, 2024 09:33

$Pyxis Oncology (PYXS.US)$ how are you guys doing?

Jaguar8

Dec 19, 2024 15:08

NEWS

$Pyxis Oncology (PYXS.US)$
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Thursday, 19th December at 4:08 pm
- The Company will focus resources on advancing its lead asset, PYX-201
- PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors
- Current cash runway expected to fund devel...